Navigation Links
Hard To Treat Diseases (HTDS) Offers Hepatitis A Vaccine in India

SHENZHEN, China, April 3 /PRNewswire-FirstCall/ - Hard To Treat Diseases (HTDS) is pleased to announce that its China based operating subsidiary Mellow Hope has surpassed sales of 200,000 units of Hepatitis A Vaccine in India.

The Hepatitis A Vaccine (BIOVAC-A) was first launched in the market of India in December, 2005. Terry Yuan, CEO added "Because our product is single-dose vaccine, so (sic) our price is almost the half of other multinational competitors' price. Our sales volume keeps growing continuously. To well promote our AV and convince the local people that our product is equal or better to our multinational competitors, we had conducted a Multi-centric clinical trial in 2007. The results proved that our product offers great safety and efficacy. Subsequently, this trial report was published in the International Journal. As a company, we hold two seminars' every year, one in India and one in China".

The company will provide further details as they become available.

Safe Harbor

Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard To Treat Diseases Inc that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. Hard To Treat Diseases Inc cautions you that any forward-looking information provided by or on behalf of Hard To Treat Diseases Inc is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard To Treat Diseases Inc's actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard To Treat Diseases Inc's control. In addition to those discussed in Hard To Treat Diseases Inc's press releases, public filings, and statements by Hard To Treat Diseases Inc's management, including, but not limited to, Hard To Treat Diseases Inc's estimate of the sufficiency of its existing capital resources, Hard To Treat Diseases Inc's ability to raise additional capital to fund future operations, Hard To Treat Diseases Inc's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard To Treat Diseases Inc's capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard To Treat Diseases Inc does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact; For any corporate matters, please contact,

SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. World-first high blood pressure treatment trialled in Melbourne
2. New Antibiotic Could Shorten TB Treatment
3. Plain-Language Guides Detail Insulin Treatments
4. More compelling evidence on why earlier HIV treatment lengthens survival
5. Treating Complicated Grief -- New NIMH Study Seeks 200 Older Adults Suffering from Unrelenting Symptoms of Complicated Grief for Participation in Non-Drug Clinical Trial
6. Solta Medical Presents Expert Roundtable about Thermage(R) and Fraxel(R) Combination Treatments at ASLMS Annual Meeting
7. Xanodynes New Drug Application for the Treatment of Heavy Menstrual Bleeding (Menorrhagia) Accepted for Filing with a Priority Review Classification
8. Some radiation therapy treatments can decrease fertility
9. Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder
10. Doctors at Henry Ford Health System Treat Ovarian, Prostate, Lung, and Other Forms of Cancer Using Novalis Tx(TM) Platform for Image-Guided Radiosurgery
11. If You Treated an Illinois Workers Compensation Patient or a Patient Covered by an Illinois Automobile Insurance Policy and Your Bill was Reduced by a Discount Pursuant to a First Health or CCN PPO Network, Please Read This Notice Carefully As It Affects
Post Your Comments:
(Date:11/26/2015)... ... November 26, 2015 , ... WorldCare International, Inc., ... the 61st annual Employee Benefits Conference. The Employee Benefits Conference was hosted by ... through Wednesday, November 11th, 2015. The conference was held at the Hawaii Convention ...
(Date:11/26/2015)... ... November 26, 2015 , ... Indosoft Inc., developer and distributor of ... server to improve system efficiency and reliability. , The new Q-Suite 6 platform is ... the system avoids locking itself into a specific piece of software for many key ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... preparing the perfect dish and pleasing the palates of attendees is of the ... a dish to a seasonal get-together, give these recipes a try this holiday ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... offering factory direct sauna parts and accessories. , Sauna accessories help improve the ... bather’s style and personality. From basic styles for the purist looking for simplicity ...
(Date:11/25/2015)... ... ... On November 10, 2015, Bohrer Brady, LLC filed a class and collective ... home health care worker who provided companionship services for the elderly, ill or disabled ... Humana, Inc., Humana at Home, Inc., and SeniorBridge Family Companies (CT), Inc. since January ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 2015  Amgen (NASDAQ: AMGN ) today announced ... the United States (U.S.) Food ... candidate to Humira ® (adalimumab). Amgen believes this ... the FDA and represents Amgen,s first BLA submission using ... , M.D., executive vice president of Research and Development ...
(Date:11/25/2015)... -- On Tuesday, November 24, 2015, the jury ... Medical Technology, Inc. for product liability and misrepresentation ... device, awarded $11 million in favor of Plaintiff ... three days of deliberations, the jury found that ... and unreasonably dangerous, and that Wright Medical made ...
(Date:11/25/2015)... Nov. 25, 2015 Allergan plc (NYSE: AGN ... the New York State Attorney General,s ... Sherman Act, and other statutes with the Attorney General over ... to cease marketing and selling the now generic version of ... admits no liability, has released its counterclaims against ...
Breaking Medicine Technology: